To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celltrion
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
diagnosed as recurrent disease or stage IV
has at least 1 measurable lesion by Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1
You may not be if
has predominantly squamous cell histology non-small cell lung cancer
had surgery for metastatic non-squamous non-small cell lung cancer (nsNSCLC)
Clareo Health | To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
